Product Images Atorvastatin Calcium

This is a description of a medication called Atorvastatin Calcium, manufactured by Nivagen Pharmaceuticals. It contains 90 tablets, each with 10mg of Atorvastatin Calcium USP. It needs to be stored at a controlled room temperature between 20°C-25°C. More information about the dosage and use can be found in the package insert. The medication comes in a child-resistant package and should be kept out of reach of children. The medication was manufactured in India by Umedica Laboratories Pvt. Ltd. However, there is no information available about the UPPCOLXXXX code.*

This is a prescription medication from Nivagen Pharmaceuticals called Atorvastatin Calcium Tablets USP. Each tablet contains 20mg of Atorvastatin Calcium USP equivalent to Atorvastatin. The manufacturer is Umedica Laboratories Pvt Lid in India. Dosage instructions can be found in the package insert and the medication should be stored at a controlled room temperature between 20°C-25°C (68°F-77°F). The contact information for Nivagen Pharmaceuticals is provided along with the manufacturing license number. Keep medication out of reach of children.*

Atorvastatin Calcium Tablets manufactured by Nivagen Pharmaceuticals. Each tablet contains Atorvastatin Calcium USP equivalent to Atorvastatin 0mg. The product is available in a container of 500 tablets and should be stored at controlled room temperature. Customers are advised to check the package insert for full prescribing information. This medicine is only available under prescription and should be kept out of children's reach. The validity of this description is until October 2021.*

This is a description for Atorvastatin Calcium Tablets with NDC 75834-258-02. It contains 80mg of Atorvastatin Calcium USP and is manufactured by Nivagen Pharmaceuticals Inc. It is stored in a controlled room temperature of 20°C-25°C (68°F-77°F). The manufacturing information is listed for Umedica Laboratories Pvt. Ltd., located in Vapi, Gujarat, India. For dosage and usage, refer to the package insert. This product is only available with a prescription and should be kept out of reach of children. The description was last updated in September 2020.*

The text appears to be a chart or graph indicating the cumulative incidence of a disease (not specified) over time in years. The data points appear to be at 20%, 30%, and 40%. Additionally, there is some text discussing a "Disease Death" in ASCOT-LLA and providing HR and p values. It is not clear from this text what this information means, and the letters "T T T J" do not provide any context.*

The text provides a graph showing the cumulative hazard percentage for Placsbo and Atorvastatin over 4 years of follow-up. The hazard rate of Atorvastatin is significantly lower than that of Placsbo, with an HR of 0.063 (p=0.001). The x-axis shows the time to the first primary endpoint, while the y-axis indicates the cumulative hazard percentage.*

This text seems to be a chart or a graph that presents data related to the incidence of a major cardiovascular event in a group of subjects who were treated with two different dosages of atorvastatin, a medication used to lower cholesterol levels. The percentages of subjects experiencing the event are shown for each dosage rate (10mg and 80mg), as well as the hazard ratio (HR) and the p-value associated with the statistical significance of the difference between the two groups. The graph also shows a time axis indicating the years from the beginning of the treatment to the occurrence of the endpoint.*